摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(4-Fluorophenyl)methyl]thieno[3,2-b]pyrrole-5-carboxylic acid | 897774-27-5

中文名称
——
中文别名
——
英文名称
4-[(4-Fluorophenyl)methyl]thieno[3,2-b]pyrrole-5-carboxylic acid
英文别名
——
4-[(4-Fluorophenyl)methyl]thieno[3,2-b]pyrrole-5-carboxylic acid化学式
CAS
897774-27-5
化学式
C14H10FNO2S
mdl
MFCD04208050
分子量
275.303
InChiKey
SXAQUTFTNUVQFM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    70.5
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
    摘要:
    该发明涉及新颖的杂环化合物及其用途,包括含有该化合物作为活性成分的药物组合物,以及用于制备用于治疗由Hedgehog(Hh)信号系统异常活性引起的人类和温血动物疾病的药物制剂。该发明还涉及上述化合物的使用形式为“分子药理学工具”,用于检查Hh信号系统的生化特征(体外和体内),特别是Hh蛋白与跨膜蛋白之间的相互作用,即抑制剂Patched(Ptc)和原癌基因蛋白。所述化合物的八个类别包括2,6-二氢-7H-吡唑并[3,4-d]吡啶嗪-7-酮和1,4-二氢吡唑并[3,4-b][1,4]噻嗪-5-酮的衍生物;N-酰化的4-咪唑并[1,2-a]嘧啶-2-基-苯胺;([4H-噻吩[3,2-b]吡咯-5-基)羰基]哌啶-4-羧酸酰胺;2-(4-羧甲基哌啶-1-基)-异尼古丁酸酰胺;N-磺酰基-1,2,3,4-四氢喹啉-6-羧酸酰胺;以及吡啶2-氨基-4,5,6,7-四氢噻吩[2,3-c] N-酰化的3-唑衍生物。
    公开号:
    US20110053915A1
  • 作为产物:
    参考文献:
    名称:
    HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
    摘要:
    该发明涉及新颖的杂环化合物及其用途,包括含有该化合物作为活性成分的药物组合物,以及用于制备用于治疗由Hedgehog(Hh)信号系统异常活性引起的人类和温血动物疾病的药物制剂。该发明还涉及上述化合物的使用形式为“分子药理学工具”,用于检查Hh信号系统的生化特征(体外和体内),特别是Hh蛋白与跨膜蛋白之间的相互作用,即抑制剂Patched(Ptc)和原癌基因蛋白。所述化合物的八个类别包括2,6-二氢-7H-吡唑并[3,4-d]吡啶嗪-7-酮和1,4-二氢吡唑并[3,4-b][1,4]噻嗪-5-酮的衍生物;N-酰化的4-咪唑并[1,2-a]嘧啶-2-基-苯胺;([4H-噻吩[3,2-b]吡咯-5-基)羰基]哌啶-4-羧酸酰胺;2-(4-羧甲基哌啶-1-基)-异尼古丁酸酰胺;N-磺酰基-1,2,3,4-四氢喹啉-6-羧酸酰胺;以及吡啶2-氨基-4,5,6,7-四氢噻吩[2,3-c] N-酰化的3-唑衍生物。
    公开号:
    US20110053915A1
点击查看最新优质反应信息

文献信息

  • HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
    申请人:Ivaschenko Andrey Alexandrovich
    公开号:US20110053915A1
    公开(公告)日:2011-03-03
    The invention relates to novel heterocyclic compounds and to the use thereof, to pharmaceutical compositions containing said chemical compounds as an active ingredient and to the use thereof for producing medicinal preparations for the human being and warm-blood animals for treating diseases caused by the aberrant activity of an Hedgehog (Hh)-signal system, in particular oncological diseases. The invention also relates to the use of the above-mentioned compounds in the form of ‘molecular pharmacological tools’ for examining (in vitro and in vivo) the biochemical features of the Hh-signal system, in particular, the interaction of Hh protein and transmembrane proteins, namely, suppressor Patched (Ptc) and protooncogenic proteins. The eight groups of the claimed compounds comprise the derivatives of 2,6-dihydro-7H-pyrazolo[3,4-d]pyridazine-7-one and 1,4-dihydropyrazolo[3,4-b][1,4]thiazine-5-one; N-acidylated 4-imidazo[1,2-a]pyrimidine-2-il-anilines; ([4H-thino[3,2-b]pyrrol-5-il) carbonyl]piperidine-4-carbonic acid amides; 2-(4carbomoilpyperidine-1-il)-isonicotinic acid amides; N-sylphonyl-1,2,3,4-tetrahydroquinoline-6-carbonic acid amides; and pyridine 2-amino-4,5,6,7-tetrahydrothieno[2,3-c] N-acidylated 3-azole derivatives.
    该发明涉及新颖的杂环化合物及其用途,包括含有该化合物作为活性成分的药物组合物,以及用于制备用于治疗由Hedgehog(Hh)信号系统异常活性引起的人类和温血动物疾病的药物制剂。该发明还涉及上述化合物的使用形式为“分子药理学工具”,用于检查Hh信号系统的生化特征(体外和体内),特别是Hh蛋白与跨膜蛋白之间的相互作用,即抑制剂Patched(Ptc)和原癌基因蛋白。所述化合物的八个类别包括2,6-二氢-7H-吡唑并[3,4-d]吡啶嗪-7-酮和1,4-二氢吡唑并[3,4-b][1,4]噻嗪-5-酮的衍生物;N-酰化的4-咪唑并[1,2-a]嘧啶-2-基-苯胺;([4H-噻吩[3,2-b]吡咯-5-基)羰基]哌啶-4-羧酸酰胺;2-(4-羧甲基哌啶-1-基)-异尼古丁酸酰胺;N-磺酰基-1,2,3,4-四氢喹啉-6-羧酸酰胺;以及吡啶2-氨基-4,5,6,7-四氢噻吩[2,3-c] N-酰化的3-唑衍生物。
  • Novel Inhibitors of Neurotropic Alphavirus Replication That Improve Host Survival in a Mouse Model of Acute Viral Encephalitis
    作者:Janice A. Sindac、Bryan D. Yestrepsky、Scott J. Barraza、Kyle L. Bolduc、Pennelope K. Blakely、Richard F. Keep、David N. Irani、David J. Miller、Scott D. Larsen
    DOI:10.1021/jm300214e
    日期:2012.4.12
    Arboviral encephalitis is a potentially devastating human disease with no approved therapies that target virus replication. We previously discovered a novel class of thieno[3,2-b]pyrrole-based inhibitors active against neurotropic alphaviruses such as western equine encephalitis virus (WEEV) in cultured cells. In this report, we describe initial development of these novel antiviral compounds, including bioisosteric replacement of the 4H-thieno[3,2-b]pyrrole core with indole to improve metabolic stability and the introduction of chirality to assess target enantioselectivity. Selected modifications enhanced antiviral activity while maintaining low cytotoidcity, increased stability to microsomal metabolism, and also revealed striking enantiospecific activity in cultured cells. Furthermore, we demonstrate improved outcomes (both symptoms and survival) following treatment with indole analogue 9h (CCG-203926) in an in vivo mouse model of alphaviral encephalitis that closely correlate with the enantiospecific in vitro antiviral activity. These results represent a substantial advancement in the early preclinical development of a promising class of novel antiviral drugs against virulent neurotropic alphaviruses.
查看更多

同类化合物

N-甲基-n-[(4-甲基-4H-噻吩并[3,2-b]吡咯-5-基)甲基]胺盐酸盐 6H-噻吩并[2,3-b]吡咯-5-羧酸甲酯 6H-噻吩并[2,3-b]吡咯-5-羧酸乙酯 6H-噻吩并[2,3-b]吡咯-5-羧酸 6-[(3-氨基苯基)甲基]-4,6-二氢-4-甲基-2-(甲基亚磺酰)-5H-噻吩并[2',3':4,5]吡咯并[2,3-D]哒嗪-5-酮 4H-噻唑[3,2-B]吡咯-5-甲酸 4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯 4H-噻吩并[3,2-B]吡咯-5-甲酰肼 4H-噻吩并[3,2-B]吡咯-5-甲酰氯 4H-噻吩并[3,2-B]吡咯-2-羧酸 4H-噻吩[3,2-b]吡咯-5-羧酸乙酯 4H-Dithieno[3,2-b:2',3'-d]吡咯,4-(1-辛基壬基)- 4-辛基-4H-二噻吩并[3,2-b:2,3-d]吡咯 4-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯 4-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 4-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸 4-甲基-4H-噻[3,2-B]吡咯-5-甲醛 4-R-4H-二噻吩并[3,2-b:2',3'-d]吡咯 3-甲基-4H-噻吩并[3,2-B]吡咯-5-羧酸乙酯 3-溴-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 3-溴-4H-噻吩并[3,2-b]吡咯-5-羧酸 3-溴-4H-噻吩并[3,2-B]吡咯-5-羧酸甲酯 3-氯-4H-噻吩并[3,2-b]吡咯-5-羧酸 2-甲酰基-4H-噻吩并[3,2-B]吡咯-5-羧酸乙酯 2-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 2-甲基-4H-噻吩并[3,2-b]吡咯-5-羧酸 2-溴-6-甲酰基-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 2-溴-6-甲酰基-4-甲基-4H-噻吩并[3,2-B]吡咯-5-羧酸乙酯 2-溴-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 2-溴-4,6-二氢-4-甲基-5H-噻吩并[2,3:4,5]吡咯并[2,3-d]吡嗪-5-酮 2-氯-6H-噻吩并[2,3-b]吡咯-5-羧酸乙酯 2-氯-6H-噻吩并[2,3-B]吡咯-5-羧酸甲酯 2-氯-4H-噻吩并[3,2-b]吡咯-5-羧酸甲酯 2-氯-4H-噻吩并[3,2-b]吡咯-5-羧酸乙酯 2-氯-4H-噻吩并[3,2-b]吡咯-5-羧酸 2-氯-3-甲基-4H-噻吩并[3,2-B]吡咯-5-羧酸乙酯 2,6-二溴-4-正辛基二噻吩并[3,2-b:2',3'-d]吡咯 2,6-二溴-4-(2-乙基己基)-4H-二噻吩并[3,2-b:2,3-d]吡咯 2,3-二氯-4H-噻吩并[3,2-b]吡咯-5-羧酸 (4-甲基-4H-噻吩并[3,2-b]吡咯-5-基)甲醇 (4-(叔丁氧基羰基)-2-氯-4H-噻吩并[3,2-B]吡咯-5-基)硼酸 3-bromo-2-methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid methyl ester 5-thiophen-3-yl-thieno[3,2-b]pyrrole-4-carboxylic acid tert-butyl ester tert-butyl 5-butyl-4H-thieno[3,2-b]pyrrole-4-carboxylate tert-butyl 4H-thieno[3,2-b]pyrrole-4-carboxylate 2-methyl-4H-thieno[3,2-b]pyrrole-5-carbohydrazide (4-methyl-piperazin-1-yl)-(3-methyl-4H-thieno[3,2-b]pyrrol-5-yl)-methanone 5-methyl-4H-thieno[3,2-b]pyrrole 4-hexyl-2,6-bis(thiophen-2-ylethynyl)-4H-dithieno[3,2-b;2′,3′-d]pyrrole 4-(3-chlorobenzyl)-2,6-bis-phenylethynylthieno[3,2-b]pyrrole-5-carboxylic acid (2-methoxyethyl)amide